摘要
目的:评估培门冬酶(Peg-asp)与左旋门冬酰胺酶(L-asp)治疗儿童初发急性淋巴细胞白血病的疗效与安全性,为临床合理应用这两种制剂提供参考依据。方法:选取2016年1—12月间湖南省儿童医院就诊的初发急性淋巴细胞白血病(acute lymphoblastic leukemia, ALL)患儿,分别采用包含L-asp (L-asp组)及Peg-asp联合化疗方案(Peg-asp组)进行诱导治疗,比较2组患儿的疗效及药物不良反应。结果:最终纳入研究的ALL患儿共427例,其中L-asp组233例、Peg-asp组194例。2组患儿第15天及第33天完全缓解率(M_1)及部分缓解率(M_2)等骨髓状态差异均无统计学意义(P>0.05)。L-asp组的过敏反应、谷丙转氨酶升高、纤维蛋白原降低、活化部分凝血活酶时间延长、抗凝血酶Ⅲ降低的发生率高于Peg-asp组,差异均有统计学意义(P<0.05);其他不良反应的指标组间差异无统计学意义(P>0. 05)。结论:L-asp与Peg-asp治疗儿童初发急性淋巴细胞白血病的疗效相当,安全性较高,不良反应类似,但Peg-asp的过敏反应、肝功能损害、凝血异常等发生率较L-asp更低。
ObjectiveTo evaluate the safety of L-asparaginase (L-asp) and pegaspargase (Peg-asp) in the treatment of acute lymphoblastic leukemia (ALL) in children,so as to provide suggestions in clinical application of the 2 medicines.MethodsNewly diagnosed ALL children from January to December in 2016 in the Hunan Children′s Hospital were selected and divided into L-asp group and Peg-asp group according to the inductive treatment program.Adverse reactions of the 2 groups were compared.ResultsA total of 427 patients were enrolled,with 233 in the L-asp group and 194 in the Peg-asp group.There was no difference of complete response (M1) and partial response (M2) marrow sratus on th 15th and 33rd day between the 2 groups (P〉0.05). Incidence of allergic reactions,increase of glutamic-pyruvic transaminase,decrease of fibrinogen,extension of activated partial thromboplastin time,reduce of antithrombin Ⅲ activity in the L-asp group is significantly higher than the Peg-asp group(P〈0.05),while the other markers reflecting the occurrence of adverse actions were not significant between the 2 groups(P〉0.05).ConclusionL-asp and Peg-asp are similar in terms of effectiveness,safety and adverse reactions in the treatment of newly diagnosed acute lymphoblastic leukemia in children.But Peg-asp has lower incidence of allergic reactions,liver function lesion,coagulation abnormality.
作者
张羽
何彦瑶
吴攀
ZHANG Yu;HE Yan-yao;WU Pan(a Department of Pharmac;b Department of Hematology,Hunan Children′s Hospital,Changsha 410007,China)
出处
《临床药物治疗杂志》
2018年第10期45-49,共5页
Clinical Medication Journal